Location History:
- Baltimore, MD (US) (2017)
- Potomac, MD (US) (2011 - 2023)
Company Filing History:
6 out of 3,687 
2 out of 3,539 
Years Active: 2011-2023
Title: The Innovative Contributions of Inventor Yardena Samuels
Introduction
Yardena Samuels, an accomplished inventor based in Potomac, MD, has made significant strides in the field of cancer research with her groundbreaking work. With a portfolio of 8 patents, she is recognized for her contributions to understanding the genetic mutations associated with cancers, particularly those linked to the PIK3CA gene. Her innovations have paved the way for new diagnostic and therapeutic approaches in oncology.
Latest Patents
Among her most notable patents is her work on the "Treatment of cancers having mutations of the PIK3CA gene." This research focuses on the role of Phosphatidylinositol 3-kinases (PI3Ks) as important regulators of signaling pathways in cancer biology. Samuels and her team analyzed the PI3K gene family, identifying that mutations in the PIK3CA gene are prevalent in various cancers such as colon cancer and other organs. The majority of these mutations cluster within the PI3K helical or kinase domains, marking PIK3CA as one of the highly mutated oncogenes in human cancers, showcasing its potential as a critical diagnostic and therapeutic target.
Career Highlights
Samuels has held pivotal roles at prominent institutions, including Johns Hopkins University and the United States Department of Health and Human Services. Her research has not only contributed to the academic understanding of cancer genetics but has also led to practical applications in disease treatment.
Collaborations
Throughout her career, Yardena Samuels has collaborated with esteemed colleagues, including Victor E. Velculescu and Kenneth W. Kinzler. These partnerships have fostered a collaborative spirit in cancer research, allowing for the integration of diverse expertise and resources in her groundbreaking work.
Conclusion
Yardena Samuels stands out as a leading innovator in the field of cancer research. With her extensive patent portfolio and collaborative efforts, she continues to influence the direction of cancer diagnosis and treatment. Her work not only enhances our understanding of genetic mutations in cancer but also holds promise for improving patient outcomes through targeted therapies.